ScHARR-TAG:
- Evolocumab for treating hyperlipidaemia and mixed dyslipidaemia (excluding homozygous familial hypercholesterolaemia) [ID765] (2016)
- Cabazitaxel for treating hormone-relapsed metastatic prostate cancer after a docetaxel-containing regimen (review of TA255)[ID889] (2016)
- Adalimumab for treating moderate to severe hidradenitis suppurativa [ID812] (2016)
- The clinical and cost-effectiveness of the LightCycler SeptiFast Test MGRADE, SepsiTest and IRIDICA BAC BSI assay for rapidly identifying bloodstream bacteria and fungi: a systematic review and economic evaluation. (2016)
DSU:
- DSU report: The use of real world data for the estimation of treatment effects in NICE decision making (June 2016, updated December 2016)
- TSD18: Methods for population-adjusted indirect comparisons in submissions to NICE (December 2016)
EEPRU:
- Mukuria C, Peasgood T, Rowen D, Brazier J. An empirical comparison of well-being measures used in the UK. Policy Research Unit in Economic Evaluation of Health and Care Interventions. Universities of Sheffield and York. EEPRU Research Report 048 (November 2016).
Other:
- Evaluating Self Management in Diabetes (ESMiD) Revised Final Report for the Health Foundation (April 2016). Sponsor: The Health Foundation
- A model to evaluate the cost effectiveness of condom distribution (CD schemes), developed for NICE public health guidance on condom distribution schemes and sexually transmitted infections (STIs) May 2016. Sponsor: NICE